CervoMed to update on clinical program

CervoMed is set to provide an update on its Neflamapimod clinical program, including new MRI analyses from the Phase 2b RewinD-LB trial. The company will also participate in a panel discussion on biomarkers at the 2026 Lewy Body Dementia Association Annual Meeting. This update will cover the status of global regulatory discussions and finalized plans for the upcoming Phase 3 trial, offering insights into the progression of their research for Lewy body dementia.